Market Place
Sourcing Support
PharmaEssentia nabs MorphoSys alum for CCO role
06 Dec 2024 //
FIERCE PHARMA
PharmaEssentia Appoints Joseph as Chief Commercial Officer
05 Dec 2024 //
BUSINESSWIRE
PharmaEssentia Announces Nine Data Presentations at ASH 2024
25 Nov 2024 //
BUSINESSWIRE
PharmaEssentia Appoints Beth A. Krewson as Head of Legal
22 Jul 2024 //
BUSINESSWIRE
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
08 Jul 2024 //
BUSINESSWIRE
PharmaEssentia Completes Enrollment for EXCEED-ET and ECLIPSE-PV Trials
25 Jun 2024 //
BUSINESSWIRE
PharmaEssentia Appoints Fred Paster as Head of Commercial
20 Jun 2024 //
BUSINESSWIRE
CORRECTED: PharmaEssentia Appoints Robert Geller as Head of Medical
24 Apr 2024 //
BUSINESSWIRE
PharmaEssentia Appoints Geller as Head of Medical, Gibbs as Head of Legal
23 Apr 2024 //
BUSINESSWIRE
PharmaEssentia’s BESREMi Recommended as a First-line Cytoreductive Therapy
27 Feb 2024 //
BUSINESSWIRE
Clinical Review of Pegylated Interferons Suggests Formulation
21 Feb 2024 //
BUSINESSWIRE
PharmaEssentia Enters Into Global License Agreement With WuXi Biologics
03 Oct 2023 //
BUSINESSWIRE
PharmaEssentia Included in FTSE Russell Indices
18 Sep 2023 //
BUSINESSWIRE
PharmaEssentia and MPN Launch New Educational Initiative
14 Sep 2023 //
BUSINESSWIRE
Study Shows Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for Polycythemia Vera
04 Aug 2023 //
BUSINESSWIRE
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi
02 Jun 2023 //
BUSINESSWIRE
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi
23 May 2023 //
BUSINESSWIRE
Nona collaborates with PharmaEssentia for Nona’s Harbour mice platform
13 May 2023 //
PHARMABIZ
PharmaEssentia Initiates Ph 3b Trial of Ropeginterferon alfa-2b-njft
03 May 2023 //
BUSINESSWIRE
PharmaEssentia Corp Announces Closing of Global Depositary Receipt Offering
21 Apr 2023 //
BUSINESSWIRE
PharmaEssentia secures $462M+ to further growth of Besremi and its pipeline
21 Apr 2023 //
ENDPTS
New Besremi campaign focuses on what counts
24 Feb 2023 //
FIERCE PHARMA
PharmaEssentia Initiates Ph2b Trial of ropeginterferon alfa-2b-njft for ET
23 Feb 2023 //
BUSINESSWIRE
PharmaEssentia takes Besremi rare blood cancer message to consumers
22 Feb 2023 //
ENDPTS
Taiwan`s PharmaEssentia opens new R&D facility in US
10 Jan 2023 //
BIOSPECTRUM ASIA
PharmaEssentia applies for marketing in China
02 Jan 2023 //
TAIPEITIMES
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care
12 Dec 2022 //
BUSINESSWIRE
Pharmaessentia to Host Investor Day in New York City on November 30, 2022
21 Nov 2022 //
BUSINESSWIRE
PharmaEssentia USA Expands Leadership With Executive Hires in Marketing
20 Oct 2022 //
BUSINESSWIRE
Review of SURPASS-ET Trial Published in Future Oncology
08 Aug 2022 //
BUSINESS WIRE
PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer
03 Aug 2022 //
BUSINESSWIRE
PharmaEssentia Honored at the NORD 2022 Rare Impact Awards
22 Jun 2022 //
BUSINESSWIRE
PharmaEssentia Appoints Meredith Manning to President of the Americas
16 May 2022 //
BUSINESSWIRE
NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi
02 Mar 2022 //
BUSINESSWIRE
PharmaEssentia Expands U.S. Leadership with Anjana Pursnani and Jason Mitch
16 Feb 2022 //
BUSINESSWIRE
German Federal Court of Justice Upholds AOP`s License Rights in Ropeginterferon
15 Feb 2022 //
BUSINESSWIRE
U.S. FDA Approves BESREMi for Adults With Polycythemia Vera
14 Nov 2021 //
BUSINESSWIRE
PharmaEssentia Announces Pipeline Presentation During Upcoming American Society
21 Oct 2021 //
BUSINESSWIRE
U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b
03 Jun 2021 //
BUSINESSWIRE
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
17 May 2021 //
PHARMACEUTICAL-TECHNOLOGY
PharmaEssentia Resubmits to the U.S. FDA For Ropeginterferon alfa-2b-njft
14 May 2021 //
BUSINESSWIRE
PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2B
13 Mar 2021 //
BUSINESSWIRE
PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b
07 Jan 2021 //
BUSINESSWIRE
PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b
07 Jan 2021 //
BUSINESSWIRE
PharmaEssentia to Present Long-Term Data on Ropeginterferon Alfa-2b
04 Nov 2020 //
BUSINESSWIRE
U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b
04 Jun 2020 //
BIOSPACE
